Kuwait Medical Electronic Library

Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses

Falah Alhajraf 1 2, Deborah Ness 3 4, Abdul Hye 5, Andre Strydom 3 4

Affiliations

expand

01 July 2019

Abstract

Individuals with Down syndrome (DS) are at high risk of developing Alzheimer's disease (AD). Discovering reliable biomarkers which could facilitate early AD diagnosis and be used to predict/monitor disease course would be extremely valuable. To examine if analytes in blood related to amyloid plaques may constitute such biomarkers, we conducted meta-analyses of studies comparing plasma amyloid beta (Aβ) levels between DS individuals and controls, and between DS individuals with and without dementia. PubMed, Embase, and Google Scholar were searched for studies investigating the relationship between Aβ plasma concentrations and dementia in DS and 10 studies collectively comprising >1,600 adults, including >1,400 individuals with DS, were included. RevMan 5.3 was used to perform meta-analyses. Meta-analyses showed higher plasma Aβ40 (SMD = 1.79, 95% CI [1.14, 2.44], Z = 5.40, p < .00001) and plasma Aβ42 levels (SMD = 1.41, 95% CI [1.15, 1.68], Z = 10.46, p < .00001) in DS individuals than controls, and revealed that DS individuals with dementia had higher plasma Aβ40 levels (SMD = 0.23, 95% CI [0.05, 0.41], Z = 2.54, p = .01) and lower Aβ42 /Aβ40 ratios (SMD = -0.33, 95% CI [-0.63, -0.03], Z = 2.15, p = .03) than DS individuals without dementia. Our results indicate that plasma Aβ40 levels may constitute a promising biomarker for predicting dementia status in individuals with DS. Further investigations using new ultra-sensitive assays are required to obtain more reliable results and to investigate to what extent these results may be generalizable beyond the DS population.

Keywords: Alzheimer's disease; Down syndrome; biomarkers; dementia; plasma/blood amyloid/Aβ.

Conflict of interest statement

All authors declare no conflicts of interest.

Figures

Figure 1 Flow chart diagram of study selection and inclusion

Figure 2 Meta‐analysis of studies comparing plasma Aβ40 levels of individuals with DS and healthy controls. Abbreviations: DS = Down syndrome, SD = standard deviation, CI = Confidence Interval, Std. = Standardized [Color figure can be viewed at http://www.wileyonlinelibrary.com]

Figure 3 Meta‐analysis of studies comparing plasma Aβ42 levels of individuals with DS and healthy controls. Abbreviations: DS = Down syndrome, SD = standard deviation, CI = Confidence Interval, Std. = Standardized [Color figure can be viewed at http://www.wileyonlinelibrary.com]

Cited by

Exploring the role of sex differences in Alzheimer's disease pathogenesis in Down syndrome.

Andrews EJ, Martini AC, Head E.Front Neurosci. 2022 Aug 12;16:954999. doi: 10.3389/fnins.2022.954999. eCollection 2022.PMID: 36033603 Free PMC article. Review.

The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease.

Rujeedawa T, Carrillo Félez E, Clare ICH, Fortea J, Strydom A, Rebillat AS, Coppus A, Levin J, Zaman SH.J Clin Med. 2021 Oct 3;10(19):4582. doi: 10.3390/jcm10194582.PMID: 34640600 Free PMC article. Review.

Blood Biomarkers for Alzheimer's Disease in Down Syndrome.

Montoliu-Gaya L, Strydom A, Blennow K, Zetterberg H, Ashton NJ.J Clin Med. 2021 Aug 17;10(16):3639. doi: 10.3390/jcm10163639.PMID: 34441934 Free PMC article. Review.

Induction of an effective anti-Amyloid-β humoral response in aged mice.

Illouz T, Madar R, Hirsh T, Biragyn A, Okun E.Vaccine. 2021 Aug 9;39(34):4817-4829. doi: 10.1016/j.vaccine.2021.07.023. Epub 2021 Jul 20.PMID: 34294479 Free PMC article.

The AT(N) framework for Alzheimer's disease in adults with Down syndrome.

Rafii MS, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Lai F, Rosas HD, Zaman S, Petersen ME, Strydom A, Fortea J, Handen B, O'Bryant S.Alzheimers Dement (Amst). 2020 Oct 27;12(1):e12062. doi: 10.1002/dad2.12062. eCollection 2020.PMID: 33134477 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

1. Alonso, A. D. C. , Zaidi, T. , Novak, M. , Grundke‐Iqbal, I. , & Iqbal, K. (2001). Hyperphosphorylation induces self‐assembly of Tau into tangles of paired helical filaments/straight filaments. Proceedings of the National Academy of Sciences, 98(12), 6923–6928. 10.1073/pnas.121119298 - DOI - PMC - PubMed
1. Alonso, A. D. C. , Zaidi, T. , Grundke‐Iqbal, I. , & Iqbal, A. K. (1994). Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proceedings of the National Academy of Sciences, 91(12), 5562–5566. 10.1073/pnas.91.12.5562 - DOI - PMC - PubMed
1. Amano, K. , Sago, H. , Uchikawa, C. , Suzuki, T. , Kotliarova, S. E. , Nukina, N. , … Yamakawa, K. (2004). Dosage‐dependent over‐expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. Human Molecular Genetics, 13(13), 1333–1340. 10.1093/hmg/ddh154 - DOI - PubMed
1. Askanas, V. , Engel, W. K. , & Nogalska, A. (2015). Sporadic inclusion‐body myositis: A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochimica et Biophysica Acta (BBA) ‐ Molecular Basis of Disease, 1852(4), 633–643. 10.1016/j.bbadis.2014.09.005 - DOI - PubMed
1. Bielewicz, J. , Kurzepa, J. , Czekajska‐Chehab, E. , Stelmasiak, Z. , & Bartosik‐Psujek, H. (2010). Does serum tau protein predict the outcome of patients with ischemic stroke? Journal of Molecular Neuroscience, 43(3), 241–245. 10.1007/s12031-010-9403-4 - DOI - PubMed
1. Billingsley, M. L. , & Kincaid, R. L. (1997). Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochemical Journal, 323(3), 577–591. 10.1042/bj3230577 - DOI - PMC - PubMed
1. Buss, L. , Fisher, E. , Hardy, J. , Nizetic, D. , Groet, J. , Pulford, L. , & Strydom, A. (2016). Intracerebral haemorrhage in Down syndrome: Protected or predisposed? F1000Research, 5, 876 10.12688/f1000research.7819.1 - DOI - PMC - PubMed
1. Cavani, S. , Tamaoka, A. , Moretti, A. , Marinelli, L. , Angelini, G. , Di Stefano, S. , … Mori, H. (2000). Plasma levels of amyloid β 40 and 42 are independent from ApoE genotype and mental retardation in down syndrome. American Journal of Medical Genetics, 95(3), 224–228. - PubMed
1. Chen, M. , Inestrosa, N. C. , Ross, G. S. , & Fernandez, H. L. (1995). Platelets are the primary source of amyloid β‐peptide in human blood. Biochemical and Biophysical Research Communications, 213(1), 96–103. 10.1006/bbrc.1995.2103 - DOI - PubMed
1. Chow, V. W. , Mattson, M. P. , Wong, P. C. , & Gleichmann, M. (2010). An overview of APP processing enzymes and products. An overview of APP processing enzymes and products. NeuroMolecular Medicine, 12(1), 1–12. 10.1007/s12017-009-8104-z - DOI - PMC - PubMed
1. Coppus, A. M. , Fekkes, D. , Verhoeven, W. M. , Tuinier, S. , & van Duijn, C. M. (2010). Plasma levels of nitric oxide related amino acids in demented subjects with Down syndrome are related to neopterin concentrations. Amino Acids, 38(3), 923–928. 10.1007/s00726-009-0300-5 - DOI - PMC - PubMed
1. Coppus, A. M. W. , Schuur, M. , Vergeer, J. , Janssens, A. C. J. W. , Oostra, B.A. , Verbeek, M.M. , & Duijn, C. M. V. (2012). Plasma amyloid and the risk of Alzheimer's disease in Down syndrome. Neurobiology of Aging, 33(9), 1988–1994. 10.1016/j.neurobiolaging.2011.08.007 - DOI - PubMed
1. Davidson, Y. S. , Robinson, A. , Prasher, V. P. , & Mann, D. M. A. (2018). The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome. Acta Neuropathologica Communications, 6(1), 56–56. 10.1186/s40478-018-0559-4 - DOI - PMC - PubMed
1. Dekker, A. D. , Sacco, S. , Carfi, A. , Benejam, B. , Vermeiren, Y. , Beugelsdijk, G. , … De Deyn, P. P. (2018). The behavioral and psychological symptoms of dementia in Down syndrome (BPSD‐DS) scale: Comprehensive assessment of psychopathology in Down syndrome. Journal of Alzheimer's Disease, 63(2), 797–819. 10.3233/JAD-170920 - DOI - PMC - PubMed
1. Doran, E. , Keator, D. , Head, E. , Phelan, M. J. , Kim, R. , Totoiu, M. , … Lott, I. T. (2017). Down syndrome, partial trisomy 21, and absence of Alzheimer's disease: The role of APP. Journal of Alzheimer's Disease, 56(2), 459–470. 10.3233/JAD-160836 - DOI - PMC - PubMed
1. Farber, N. B. , Rubin, E. H. , Newcomer, J. W. , Kinscherf, D. A. , Miller, J. P. , Morris, J. C. , … McKeel, D. W. (2000). Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Archives of General Psychiatry, 57(12), 1165 10.1001/archpsyc.57.12.1165 - DOI - PubMed
1. Fortea, J. , Carmona‐Iragui, M. , Benejam, B. , Fernández, S. , Videla, L. , Barroeta, I. , … Lleó, A. (2018). Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: A cross‐sectional study. The Lancet Neurology, 17(10), 860–869. 10.1016/S1474-4422(18)30285-0 - DOI - PubMed
1. Fukumoto, H. , Tennis, M. , Locascio, J. J. , Hyman, B. T. , Growdon, J. H. , & Irizarry, M. C. (2003). Age but not diagnosis is the main predictor of plasma amyloid beta‐protein levels. Archives of Neurology, 60(7), 958–964. 10.1001/archneur.60.7.958 - DOI - PubMed
1. Gabelle, A. , Schraen, S. , Gutierrez, L.‐A. , Pays, C. , Rouaud, O. , Buee, L. , … Berr, C. (2015). Plasma b‐amyloid 40 levels are positively associated with mortality risks in the elderly. Alzheimer's & Dementia, 11(6), 672–680. 10.1016/j.jalz.2014.04.515 - DOI - PubMed
1. Growdon, J. , Selkoe, D. , Roses, A. , Trojanowski, J. , Davies, P. & S. A. e. a. W. G. A. Committee . (1998). Consensus report of the working group on: “molecular and biochemical markers of Alzheimer's disease”. Neurobiology of Aging, 19(2), 109–116. 10.1016/S0197-4580(98)00022-0 - DOI - PubMed
1. Grundke‐Iqbal, I. , Iqbal, K. , Tung, Y. C. , Quinlan, M. , Wisniewski, H. M. , & Binder, L. I. (1986). Abnormal phosphorylation of the microtubule‐associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences, 83(13), 4913–4917. 10.1073/pnas.83.13.4913 - DOI - PMC - PubMed
1. Hamlett, E. , Goetzl, E. , Ledreux, A. , Vasilevko, V. , Boger, H. , LaRosa, A. , … Granholm, A. (2017). Neuronal exosomes reveal Alzheimer's disease biomarkers in down syndrome. Alzheimer's & Dementia, 13(5), 541–549. - PMC - PubMed
1. Hanon, O. , Vidal, J.‐S. , Lehmann, S. , Bombois, S. , Allinquant, B. , Tréluyer, J.‐M. , … Schraen‐Maschke, S. (2018). Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. Alzheimer's & Dementia, 14(7), 858–868. 10.1016/j.jalz.2018.01.004 - DOI - PubMed
1. Head, E. , Doran, E. , Nistor, M. , Hill, M. , Schmitt, F. , Haier, R. J. , & Lott, I. T. (2011). Plasma Aβ as a function of age, level of intellectual disability and presence of dementia in Down syndrome. Journal of Alzheimer's Disease, 23(3), 399–409. 10.3233/JAD-2010-101335 - DOI - PMC - PubMed
1. Iulita, M. F. , Ower, A. , Barone, C. , Pentz, R. , Gubert, P. , Romano, C. , … Cuello, A. C. (2016). An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimer's & Dementia, 12(11), 1132–1148. 10.1016/j.jalz.2016.05.001 - DOI - PubMed
1. Iwatsubo, T. , Odaka, A. , Suzuki, N. , Mizusawa, H. , Nukina, N. , & Ihara, Y. (1994). Visualization of Aβ42(43) and Aβ40 in senile plaques with end‐specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron, 13(1), 45–53. 10.1016/0896-6273(94)90458-8 - DOI - PubMed
1. Jarrett, J. T. , Berger, E. P. , & Lansbury, P. T. (1993). The carboxy terminus of the.beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry, 32(18), 4693–4697. 10.1021/bi00069a001 - DOI - PubMed
1. Jones, E. L. , Hanney, M. , Francis, P. T. , & Ballard, C. G. (2009). Amyloid concentrations in older people with Down syndrome and dementia. Neuroscience Letters, 451(2), 162–164. 10.1016/j.neulet.2008.12.030 - DOI - PubMed
1. Kasai, T. , Tatebe, H. , Kondo, M. , Ishii, R. , Ohmichi, T. , Yeung, W. T. E. , … Tokuda, T. (2017). Increased levels of plasma total tau in adult Down syndrome. PLoS One, 12(11), e0188802 10.1371/journal.pone.0188802 - DOI - PMC - PubMed
1. Kok, E. , Haikonen, S. , Luoto, T. , Huhtala, H. , Goebeler, S. , Haapasalo, H. , & Karhunen, P. J. (2009). Apolipoprotein E‐dependent accumulation of Alzheimer disease‐related lesions begins in middle age. Annals of Neurology, 65(6), 650–657. 10.1002/ana.21696 - DOI - PubMed
1. Kucheryavykh, L. Y. , Dávila‐Rodríguez, J. , Rivera‐Aponte, D. E. , Zueva, L. V. , Washington, A. V. , Sanabria, P. , & Inyushin, M. Y. (2017). Platelets are responsible for the accumulation of β‐amyloid in blood clots inside and around blood vessels in mouse brain after thrombosis. Brain Research Bulletin, 128, 98–105. 10.1016/j.brainresbull.2016.11.008 - DOI - PMC - PubMed
1. Kuo, Y.‐M. , Kokjohn, T. A. , Watson, M. D. , Woods, A. S. , Cotter, R. J. , Sue, L. I. , … Roher, A. E. (2000). Elevated Ab‐42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of APP metabolism. American Journal of Pathology, 156(3), 797–805. - PMC - PubMed
1. Lautarescu, B. A. , Holland, A. J. , & Zaman, S. H. (2017). The early presentation of dementia in people with Down syndrome: A systematic review of longitudinal studies. Neuropsychology Review, 27(1), 31–45. 10.1007/s11065-017-9341-9 - DOI - PMC - PubMed
1. Lee, N. , Chien, Y. , & Hwu, W. (2017). A review of biomarkers for Alzheimer’s disease in down syndrome. Neurology and Therapy, 6(S1), 69–81. - PMC - PubMed
1. Lemere, C. A. , Blusztajn, J. K. , Yamaguchi, H. , Wisniewski, T. , Saido, T. C. , & Selkoe, D. J. (1996). Sequence of deposition of heterogeneous amyloid b‐peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiology of Disease, 3(1), 16–32. 10.1006/nbdi.1996.0003 - DOI - PubMed
1. Li, H. , Zhu, H. , Wallack, M. , Mwamburi, M. , Abdul‐Hay, S. O. , Leissring, M. A. , & Qiu, W. Q. (2015). Age and its association with low insulin and high amyloid‐β peptides in blood. Journal of Alzheimer's Disease, 49(1), 129–137. 10.3233/JAD-150428 - DOI - PMC - PubMed
1. Li, Q. X. , Whyte, S. , Tanner, J. E. , Evin, G. , Beyreuther, K. , & Masters, C. L. (1998). Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Laboratory Investigation, 78(4), 461–469. - PubMed
1. Liliang, P.‐C. , Liang, C.‐L. , Weng, H.‐C. , Lu, K. , Wang, K.‐W. , Chen, H.‐J. , & Chuang, J.‐H. (2010). τ proteins in serum predict outcome after severe traumatic brain injury. Journal of Surgical Research, 160(2), 302–307. 10.1016/j.jss.2008.12.022 - DOI - PubMed
1. Lövheim, H. , Elgh, F. , Johansson, A. , Zetterberg, H. , Blennow, K. , Hallmans, G. , & Eriksson, S. (2017). Plasma concentrations of free amyloid Beta cannot predict the development of Alzheimer's disease. Alzheimer's & Dementia, 13(7), 778–782. 10.1016/j.jalz.2016.12.004 - DOI - PubMed
1. Lue, L.‐F. , Guerra, A. , & Walker, D. G. (2017). Amyloid beta and tau as Alzheimer's disease blood biomarkers: promise from new technologies. Neurology and Therapy, 6(S1), 25–36. 10.1007/s40120-017-0074-8 - DOI - PMC - PubMed
1. Lyle, R. , Gehrig, C. , Neergaard‐Henrichsen, C. , Deutsch, S. , & Antonarakis, S. E. (2004). Gene expression from the Aneuploid chromosome in a trisomy mouse model of Down syndrome. Genome Research, 14(7), 1268–1274. 10.1101/gr.2090904 - DOI - PMC - PubMed
1. Mann, D.M. , Davidson, Y.S. , Robinson, A.C. , Allen, N. , Hashimoto, T. , Richardson, A. ., … Laquerrière, A. (2018). Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease. Acta Neuropathologica, 136(4), 569–587. - PMC - PubMed
1. Matsubara, E. , Sekijima, Y. , Tokuda, T. , Urakami, K. , Amari, M. , Shizuka-Ikeda, M. , … Shoji, M. (2004). Soluble Aβ homeostasis in AD and DS: Impairment of anti-amyloidogenic protection by lipoproteins. Neurobiology of Aging, 25(7), 833–841. - PubMed
1. Matsuoka, Y. , Andrews, H. F. , Becker, A. G. , Gray, A. J. , Mehta, P. D. , Sano, M. C. , … Aisen, P. S. (2009). The relationship of plasma Aβ levels to dementia in aging individuals with Down syndrome. Alzheimer Disease and Associated Disorders, 23(4), 315–318. 10.1097/WAD.0b013e3181aba61e - DOI - PMC - PubMed
1. Mattsson, N. , Andreasson, U. , Zetterberg, H. , & Blennow, K. (2017). Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurology, 74(5), 557–566. 10.1001/jamaneurol.2016.6117 - DOI - PMC - PubMed
1. Mehta, P. , Dalton, A. , Mehta, S. , Kim, K. , Sersen, E. , & Wisniewski, H. (1998). Increased plasma amyloid β protein 1–42 levels in Down syndrome. Neuroscience Letters, 241(1), 13–16. - PubMed
1. Mehta, P. D. , Capone, G. , Jewell, A. , & Freedland, R. L. (2007). Increased amyloid β protein levels in children and adolescents with Down syndrome. Journal of the Neurological Sciences, 254(1–2), 22–27. 10.1016/j.jns.2006.12.010 - DOI - PubMed
1. Mehta, P. D. , Mehta, S. P. , Fedor, B. , Patrick, B. A. , Emmerling, M. , & Dalton, A. J. (2003). Plasma amyloid b protein 1–42 levels are increased in old Down syndrome but not in young Down syndrome. Neuroscience Letters, 342(3), 155–158. 10.1016/S0304-3940(03)00275-1 - DOI - PubMed
1. Mehta, P. , Pirttila, T. , Patrick, B. , Barshatzky, M. , & Mehta, S. (2001). Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neuroscience Letters, 304(1–2), 102–106. 10.1016/s0304-3940(01)01754-2 - DOI - PubMed
1. Morris, J. K. , & Springett, A. (2013). 2013 Annual Report. The national Down syndrome cytogenetic register for England and Wales. Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London.
1. Nakamura, A. , Kaneko, N. , Villemagne, V. L. , Kato, T. , Doecke, J. , Dore, V. , … Yanagisawa, K. (2018). High performance plasma amyloid‐beta biomarkers for Alzheimer's disease. Nature, 554(7691), 249–254. 10.1038/nature25456 - DOI - PubMed
1. Nostrand, W. E. V. (2016). The influence of the amyloid β‐protein and its precursor in modulating cerebral hemostasis. Biochimica Et Biophysica Acta, 1862(5), 1018–1026. 10.1016/j.bbadis.2015.10.020 - DOI - PMC - PubMed
1. Obeid, R. , Hübner, U. , Bodis, M. , & Geisel, J. (2016). Plasma amyloid beta 1–42 and DNA methylation pattern predict accelerated aging in young subjects with down syndrome. NeuroMolecular Medicine, 18(4), 593–601. - PubMed
1. O'Bryant, S. E. , Mielke, M. M. , Rissman, R. A. , Lista, S. , Vanderstichele, H. , Zetterberg, H. , … Hampel, H. (2017). Blood based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's & Dementia, 13(1), 45–58. 10.1016/j.jalz.2016.09.014 - DOI - PMC - PubMed
1. Ovod, V. , Ramsey, K. , Mawuenyega, K. , Bollinger, J. , Hicks, T. , Schneider, T. , … Bateman, R. (2017). Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to CNS amyloidosis. Alzheimer's & Dementia, 13, 841–849. 10.1016/j.jalz.2017.06.2266 - DOI - PMC - PubMed
1. Prasher, V. P. , Farrer, M. J. , Kessling, A. M. , Fisher, E. M. , West, R. J. , Barber, P. C. , & Butler, A. C. (1998). Molecular mapping of Alzheimer‐type dementia in Down's syndrome. Annals of Neurology, 43(3), 380–383. 10.1002/ana.410430316 - DOI - PubMed
1. Prasher, V. P. , Sajith, S. G. , Mehta, P. , Zigman, W. B. , & Schupf, N. (2010). Plasma beta amyloid and duration of Alzheimer's disease in adults with Down syndrome. International Journal of Geriatric Psychiatry, 25(2), 202–207. 10.1002/gps.2321 - DOI - PMC - PubMed
1. Rafii, M. , Lukic, A. , Andrews, R. , Brewer, J. , Rissman, R. , Strother, S. , … Matthews, D. (2017). PET imaging of tau pathology and relationship to amyloid, longitudinal MRI, and cognitive change in down syndrome: Results from the down syndrome biomarker Initiative (DSBI). Journal of Alzheimer's Disease, 60(2), 439–450. - PubMed
1. Review Manager (RevMan) [Computer program] . (2014). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration.
1. Schmechel, D. E. , Saunders, A. M. , Strittmatter, W. J. , Crain, B. J. , Hulette, C. M. , Joo, S. H. , … Roses, A. D . (1993). Increased amyloid beta‐peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late‐onset Alzheimer disease. Proceedings of the National Academy of Sciences, 90(20), 9649–9653. 10.1073/pnas.90.20.9649 - DOI - PMC - PubMed
1. Schupf, N. , Patel, B. , Pang, D. , Zigman, W. B. , Silverman, W. , Mehta, P. D. , & Mayeux, R. (2007). Elevated plasma amyloid.‐peptide A.42, incident dementia and mortality in Down syndrome. Archives of Neurology, 64(7), 1007–1013. 10.1001/archneur.64.7.1007 - DOI - PMC - PubMed
1. Schupf, N. , Patel, B. , Silverman, W. , Zigman, W. B. , Zhong, N. , Tycko, B. , … Mayeux, R. (2001). Elevated plasma amyloid b‐peptide 1±42 and onset of dementia in adults with Down syndrome. Neuroscience Letters, 301(3), 199–203. 10.1016/s0304-3940(01)01657-3 - DOI - PubMed
1. Schupf, N. , Zigman, W. B. , Tang, M. X. , Pang, D. , Mayeux, R. , Mehta, P. , & Silverman, W. (2010). Change in plasma A peptides and onset of dementia in adults with Down syndrome. Neurology, 75(18), 1639–1644. 10.1212/wnl.0b013e3181fb448b - DOI - PMC - PubMed
1. Sheehan, R. , Sinai, A. , Bass, N. , Blatchford, P. , Bohnen, I. , Bonell, S. , … Strydom, A. (2015). Dementia diagnostic criteria in Down syndrome. International Journal of Geriatric Psychiatry, 30(8), 857–863. 10.1002/gps.4228 - DOI - PMC - PubMed
1. Sherman, S. L. , Allen, E. G. , Bean, L. H. , & Freeman, S. B. (2007). Epidemiology of Down syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 13(3), 221–227. 10.1002/mrdd.20157 - DOI - PubMed
1. Sperling, R. A. , Aisen, P. S. , Beckett, L. A. , Bennett, D. A. , Craft, S. , Fagan, A. M. , … Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7(3), 280–292. 10.1016/j.jalz.2011.03.003 - DOI - PMC - PubMed
1. Startin, C. M. , Hamburg, S. , Hithersay, R. , Al‐Janabi, T. , Mok, K. Y. , Hardy, J. , … Zhang, D. (2019). Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's & Dementia, 15(2), 245–257. 10.1016/j.jalz.2018.08.009 - DOI - PMC - PubMed
1. Strydom, A. , Heslegrave, A. , Startin, C. M. , Mok, K. Y. , Hardy, J. , Groet, J. , … Zetterberg, H. (2018). Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimer's Research & Therapy, 10(1), 39 10.1186/s13195-018-0367-x - DOI - PMC - PubMed
1. Sultan, M. , Piccini, I. , Balzereit, D. , Herwig, R. , Saran, N. G. , Lehrach, H. , … Yaspo, M.‐L. (2007). Gene expression variation in Down's syndrome mice allows prioritization of candidate genes. Genome Biology, 8(5), R91 10.1186/gb-2007-8-5-r91 - DOI - PMC - PubMed
1. Tatebe, H. , Kasai, T. , Ohmichi, T. , Kishi, Y. , Kakeya, T. , Waragai, M. , … Tokuda, T. (2017). Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: Pilot case‐control studies including patients with Alzheimer's disease and down syndrome. Molecular Neurodegeneration, 12(1), 10.1186/s13024-017-0206-8 - DOI - PMC - PubMed
1. Tokuda, T. , Fukushima, T. , Ikeda, S.‐I. , Sekijima, Y. , Shoji, S. I. , Yanagisawa, N. , & Tamaoka, A. (1997). Plasma levels of amyloid β proteins Aβ l‐40 and Aβ 1–42(43) are elevated in Down's syndrome. Annals of Neurology, 41(2), 271–273. 10.1002/ana.410410220 - DOI - PubMed
1. Tomlinson, B. E. , Blessed, G. , & Roth, M. (1970). Observations on the brains of demented old people. Journal of the Neurological Sciences, 11(3), 205–242. 10.1016/0022-510x(70)90063-8 - DOI - PubMed
1. Wang, J.‐Z. , Grundke‐Iqbal, I. , & Iqbal, K. (2007). Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. European Journal of Neuroscience, 25(1), 59–68. 10.1111/j.1460-9568.2006.05226.x - DOI - PMC - PubMed
1. Weston, P. S. J. , Poole, T. , Ryan, N. S. , Nair, A. , Liang, Y. , Macpherson, K. , … Fox, N. C. (2017). Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology, 89(21), 2167–2175. 10.1212/WNL.0000000000004667 - DOI - PMC - PubMed
1. Wiseman, F. K. , Al‐Janabi, T. , Hardy, J. , Karmiloff‐Smith, A. , Nizetic, D. , Tybulewicz, V. L. J. , … Strydom, A. (2015). A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. Nature Reviews Neuroscience, 16(9), 564–574. 10.1038/nrn3983 - DOI - PMC - PubMed
1. Wiseman, F. K. , Pulford, L. J. , Barkus, C. , Liao, F. , Portelius, E. , Webb, R. , … Fisher, E. M. C. (2018). Trisomy of human chromosome 21 enhances amyloid‐b deposition independently of an extra copy of APP. Brain, 141(8), 2457–2474. 10.1093/brain/awy159 - DOI - PMC - PubMed
1. Zis, P. , Dickinson, M. , Shende, S. , Walker, Z. , & Strydom, A. (2012). Oxidative stress and memory decline in adults with Down syndrome: Longitudinal study. Journal of Alzheimer's Disease, 31(2), 277–283. 10.3233/JAD-2012-120073 - DOI - PubMed
1. Zis, P. , McHugh, P. , McQuillin, A. , Praticò, D. , Dickinson, M. , Shende, S. , … Strydom, A. (2014). Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress. PLoS One, 9(6), e97709 10.1371/journal.pone.0097709 - DOI - PMC - PubMed
1. Zis, P. , & Strydom, A. (2018). Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. Free Radical Biology and Medicine, 114, 3–9. 10.1016/j.freeradbiomed.2017.08.024 - DOI - PMC - PubMed

Show All